Can someone explain to a novice how the share price can go up when all transactions today have been sells
Thats a very good point you make - often the public is prepared to spend more money looking after their pets than they do on themselves. If the science continues to show value in developing products that offer a material benefit on reducing pain in some way, then people are going to use this to aid their dog, their cat and other beloved pets. It is an important reason why such companies invest in developing products with a multi-layered approach.
Totally agree - reality is that they need to do better at selling themselves and promoting the work that is being done. An RNS is a great opportunity to keep shareholders on side, not just a necessary regulatory chore to get through - YGEN has great potential yet the share price has hardly moved because the markets are still edgy about this share. I have been a long holder of YGEN and will continue to be, but they have got to do better in selling themselves - much better
A one day ramping and it will fall back to earth by Friday with a bump - just shows the power of rampers on a new share, in order to take short term profits
Give them a chance to turn this into something positive. They are working to an internal plan - building on their infrastructure to deliver value going forward. Not every share makes daily gains - you jump on when you believe the time is right and if it drops then your timing is not quite right but everything on AIM is a gamble and you have to stick by your guns or bail out - if you are prepared to wait then this may well turn into a really positive company - give them a chance to show you (or bail)
Thank you that is great
Hi all - can someone explain why there are so many tiny buys i. e. Less that £20 - surely it costs a transaction fee which is over £10 - this surely cannot be financially viable. Am I being thick and missing something here.
Thanks Cheapie - fingers crossed they will be good to their word
Exciting times ahead
Could anyone tell me when is the anticipated relist date for this share
m I missing a trick - why would individuals purchase single shares , at a cost of 7p - this must cost you £10 transaction fee to do this
There are lot s of these very low quantity shares - what am i missing?
See Holland and Barrett website https://www.hollandandbarrett.com/
Front page launch of Slimbiome - great launch, targeted at a time when over indulgent Christmas' prompt people to look at ways to shed a few pounds - great timing
Agreed Twix - I have some hope that we have now crossed that line, where we see past troubles begin to slowly fade. Now is the time to build a solid platform on which to take the business forward - which they finally seem to be doing. Fingers and toes now crossed in a hope that the next year will see real progress
Finally, the beginning of an exciting period of growth, built on a widening portfolio - looking good
RNS Number : 0835Y
OptiBiotix Health PLC
07 May 2019
OptiBiotix Health plc
("OptiBiotix" or the "Company")
License agreement for LP(LDL) (R) in personalised nutrition applications
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd., has signed a license agreement with Instituto Español de Nutrición Personalizada, S.A. ("IENP") for the use of Lactobacillus plantarum ("LP(LDL) (R)") in personalised food supplements in Spain.
The agreement grants IENP non-exclusive rights to manufacture and market food supplements containing OptiBiotix's cholesterol and blood pressure-reducing probiotic strain LP(LDL) (R) in Spain for a period of three years. IENP is the precision nutrition branch of CAPSA Food, one of the largest food conglomerates in Spain, owner of leading dairy brands such as Central Lechera Asturiana and Larsa, with annual revenues of over EUR700m. In 2017, they were awarded 'Leading company in the Food Sector' with the ORO +500 SEAL of European Excellence and the Reptrak first prize for the company with the best reputation in Spain by the Reputation Institute (see https://www.capsafood.com/company/awards)
IENP have developed an innovative genomic test to analyse the gut microbiome, the bacteria living in the intestine, to detect imbalances which may potentially lead to different health conditions. Based on results, customers are placed on different, targeted food supplement regimens to take their microbiome composition back to healthy. IENP have developed COL-15, a microbiome-modulating food supplement commercialised under the "39ytú" brand. IENP will use their extensive network to market the product in supermarkets, department stores, pharmacies, and online across Spain.
Personalised nutrition is a nascent field which holds the promise to revolutionise the way food, health and wellness are conceived. According to Reseach And Markets (2018), the global market for personalised nutrition is expected to grow by CAGR ca. 10% to USD$50bn by 2025, with food supplements its fastest-growing segment.
Dr. Luis Gosálbez, Business Development Director of OptiBiotix, commented: "We are delighted to enter the field of personalised and precision nutrition, one of the fastest-growing and highest-value sectors within the food industry. We chose IENP due to its industry reputation, decades of experience in the Spanish food market, and its ability to rapidly launch products and build sales. Within two years of launch, we now have products being sold by numerous partners in over 30 countries around the world. This builds revenues and increases the value of our trademarked and patented assets, like LP(LDL) (R), as it grows into a global brand. We see this agreement as another step to growing revenues, market presence, and brand value of LP(LDL) (R), the 'Intel' inside a wide ran
Surely every new contract of any size continues to validate the technology and gives confidence to the wider market that Cyan have a template for use in other similar installations.
If they were not announcing any new business then everyone would be getting annoyed - be pleased that there is at least a contract commencing Q3 2019 that will add value to the validation of the technology and supply chain programme
A game changer ? sounds like this is a real milestone in the progress and use of LPLDL
A very positive RNS
DaCosta - then please enlighten me - I have been with Premaitha for years hoping that this will go the same way as Opti at some stage - what do you think?
What does anyone think of the announcement - could someone enlighten me as to what the purpose of this announcement is - seems a nothing RNS - but I may have missed the point completely.